Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.58 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.46 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.46 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12376661 | 0.87 | RIPK1 (0.44) | RIPK1GAAKCNJ6KCNJ5KCNJ3 | |
| SCHEMBL12986725 | 0.82 | NTRK1 (0.55) | NTRK1GAATSHRKCNJ6KCNJ5 | |
| SCHEMBL13101587 | 0.78 | RIPK1 (0.51) | RIPK1GAAKMT2AALDH1A1MEN1 | |
| SCHEMBL13467666 | 0.75 | RAB9A (0.57) | NTRK1GAAKMT2AMEN1 | |
| SCHEMBL2854522 | 0.74 | MAPK1 (0.64) | MAPK1 | |
| SCHEMBL23391777 | 0.74 | RIPK1 (1.00) | RIPK1MAPK1 | |
| SCHEMBL12848336 | 0.72 | MAPT (0.49) | RIPK1GAAKCNJ6KCNJ5KCNJ3 | |
| SCHEMBL15441318 | 0.72 | ALDH1A1 (0.47) | NTRK1GAATSHRKCNJ6KCNJ5 | |
| SCHEMBL10202150 | 0.70 | POLB (0.69) | ALDH1A1 | |
| SCHEMBL21366468 | 0.70 | NR4A3 (0.52) | RIPK1GAAALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | RIPK1 2517/4885NTRK1 56/4885GAA 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.